Novel formulation for sustained, steady-state drug release

Lyndra Therapeutics is developing an orally administered dosage form that delivers sustained, steady-state release of one or more drugs for a week or longer while temporarily residing in the stomach. The foundation is supporting the company’s work on this new drug delivery for global health conditions in low-income countries.
  • Domain
  • Investment type
    Direct equity
  • Status
  • Initial investment
    Series B
  • Partnered in
  • Investment lead
    Ryan Kreitzer
  • Headquarters
  • Program strategy
    Integrated Development

More about our work

Our focus

Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.

Investment approach

Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.

Our team

We bring depth of experience to every investment, with a proven track record across sectors and scale.